Doximity Stock Plunges After Analyst Downgrade

Shares of the telehealth platform company hit a new 52-week low following a rating cut from Evercore.

Apr. 8, 2026 at 2:57pm by Ben Kaplan

Got story updates? Submit your updates here. ›

Doximity, Inc. (NYSE:DOCS) saw its stock price plummet after Evercore downgraded the company's shares from 'outperform' to 'in-line' and set a $25 price target. The stock hit a new 52-week low of $21.66 during trading on Wednesday. Several other analysts have also recently lowered their price targets on Doximity amid concerns about the company's growth prospects.

Why it matters

Doximity is a leading provider of digital communication tools for healthcare professionals, but the company has faced increasing competition in the telehealth space. The analyst downgrade and new low stock price reflect broader uncertainty about Doximity's ability to maintain its market position and continue growing its user base and revenue.

The details

Evercore analyst Elizabeth Anderson cited 'execution challenges' as the reason for the downgrade, noting that Doximity's growth has slowed compared to earlier forecasts. The stock price drop comes after Doximity reported weaker-than-expected guidance for its current fiscal year. Several other analysts, including those from Wells Fargo and BMO Capital Markets, have also lowered their price targets on Doximity in recent months.

  • Doximity stock hit a new 52-week low of $21.66 on Wednesday, April 8, 2026.
  • Evercore downgraded Doximity from 'outperform' to 'in-line' and set a $25 price target on the same day.

The players

Doximity, Inc.

A digital platform that provides communication tools and medical information for healthcare professionals.

Evercore

An independent investment banking advisory firm that downgraded Doximity's stock.

Elizabeth Anderson

An Evercore analyst who cited 'execution challenges' as the reason for the Doximity downgrade.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

The downgrade and new 52-week low for Doximity's stock price reflect growing concerns about the company's ability to maintain its leadership position in the competitive telehealth market. Investors will be closely watching Doximity's upcoming financial results and guidance to see if the company can regain momentum and reassure Wall Street about its long-term growth prospects.